Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved..
Bivalent COVID vaccines containing mRNA for ancestral and Omicron BA.5 spike proteins do not induce stronger T cell responses to Omicron BA.5 spike proteins than monovalent vaccines that contain only ancestral spike mRNA. The reasons for this finding have not been elucidated. Here, we show that healthy donors (HDs) and people living with HIV (PLWH) on antiretroviral therapy mostly target T cell epitopes that are not affected by BA.5 mutations. We use the functional expansion of specific T cells (FEST) assay to determine the percentage of CD4+ T cells that cross-recognize both spike proteins and those that are monoreactive for each protein. We show a predominance of cross-reactive CD4+ T cells; less than 10% percent of spike-specific CD4+ T cell receptors were BA.5 monoreactive in most HDs and PLWH. Our data suggest that the current bivalent vaccines do not induce robust BA.5-monoreactive T cell responses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 5(2024), 3 vom: 19. März, Seite 101442 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sop, Joel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BA.5 |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2024.101442 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369129164 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369129164 | ||
| 003 | DE-627 | ||
| 005 | 20240403235538.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2024.101442 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM369129164 | ||
| 035 | |a (NLM)38423018 | ||
| 035 | |a (PII)S2666-3791(24)00065-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sop, Joel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Bivalent COVID vaccines containing mRNA for ancestral and Omicron BA.5 spike proteins do not induce stronger T cell responses to Omicron BA.5 spike proteins than monovalent vaccines that contain only ancestral spike mRNA. The reasons for this finding have not been elucidated. Here, we show that healthy donors (HDs) and people living with HIV (PLWH) on antiretroviral therapy mostly target T cell epitopes that are not affected by BA.5 mutations. We use the functional expansion of specific T cells (FEST) assay to determine the percentage of CD4+ T cells that cross-recognize both spike proteins and those that are monoreactive for each protein. We show a predominance of cross-reactive CD4+ T cells; less than 10% percent of spike-specific CD4+ T cell receptors were BA.5 monoreactive in most HDs and PLWH. Our data suggest that the current bivalent vaccines do not induce robust BA.5-monoreactive T cell responses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BA.5 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a T cell receptor | |
| 650 | 4 | |a bivalent vaccine | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Traut, Caroline C |e verfasserin |4 aut | |
| 700 | 1 | |a Dykema, Arbor G |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Joanne H |e verfasserin |4 aut | |
| 700 | 1 | |a Beckey, Tyler P |e verfasserin |4 aut | |
| 700 | 1 | |a Basseth, Christie R |e verfasserin |4 aut | |
| 700 | 1 | |a Antar, Annukka A R |e verfasserin |4 aut | |
| 700 | 1 | |a Laeyendecker, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kellie N |e verfasserin |4 aut | |
| 700 | 1 | |a Blankson, Joel N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 5(2024), 3 vom: 19. März, Seite 101442 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:3 |g day:19 |g month:03 |g pages:101442 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2024.101442 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 3 |b 19 |c 03 |h 101442 | ||